Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Case Report

Rare Clinical Case of Cryopyrin-associated Periodic Syndrome Presented with Ankylosing Spondylitis: A Case Report

Author(s): Anna A. Zayaeva, Lyudmila V. Sokolova, Denis V. Shaduro, Andrey V. Petrov, Shanmugaraj Kulanthaivel* and Vitalii B. Kaliberdenko

Volume 18, Issue 4, 2022

Published on: 30 November, 2021

Page: [373 - 379] Pages: 7

DOI: 10.2174/1573397117666211116110833

Price: $65

Open Access Journals Promotions 2
Abstract

Background: Cryopyrin-Associated Periodic Syndrome (CAPS) is a variety of clinical variants of autoinflammatory diseases. The pathology is based on a mutation in the NLRP3 gene encoding the cryopyrin protein, which leads to the uncontrolled production of interleukin-1β. Particular attention should be paid to the rarity of this disease and the lack of clinical knowledge about it in therapeutic and rheumatological practice, which leads to an erroneous diagnosis and the appointment of ineffective treatment for a long time, leading to the progression of the disease and disability of the patient.

Case Presentation: This article describes a clinical case of this disease. The first manifestations of the disease in a woman appeared from the age of 2 years, in the form of a rash and fever. Since school age, there have been signs of arthritis. By the age of 24, sensorineural hearing loss and pain in the spine were evident. The disease occurred under the clinical manifestations of spondyloarthritis. Its treatment with anti-inflammatory therapy did not give a stable result.

Conclusion: From the analysis, we can conclude that patient M. from early childhood suffers from a severe Neonatal-onset Multisystem Inflammatory Disease of a genetic nature. For a long time, the patient was diagnosed with ankylosing spondylitis, and appropriate treatment was carried out without significant success. The correct diagnosis of CAPS was made only in 2018. This patient has conditions of both CAPS and AS together, which is a very rare association in rheumatological practice. The only treatment method that could stop the manifestations of the disease and prevent life-threatening kidney damage (amyloidosis) is the use of genetically engineered biological drugs, i.e., IL-1β inhibitors. The only drug of this group registered in Russia is canakinumab (Ilaris®). From the moment of diagnosis to the present day, the patient is treated with the genetically engineered drug canakinumab (Ilaris®) at a dose of 150 mg once every 8 weeks. 6 months after taking the drug, the patient went into complete clinical and laboratory remission.

Keywords: Cryopyrin-associated periodic syndrome, IL-1β, IL-1β inhibitor, canakinumab, NLRP3 gene mutation, NSAIDs, ankylosing spondylitis, Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS).

Graphical Abstract
[1]
Kümmerle-Deschner JB, Lohse P. Genetics of cryopyrin-associated periodic syndrome. Z Rheumatol 2017; 76(4): 313-21.
[http://dx.doi.org/10.1007/s00393-017-0271-y]
[2]
Kozlova AL, Mamzerova ES, Novichkova GA, Shherbina A. Clinical manifestations and therapy of cryopyrin-associated periodic fever syndromes. Pediatr Hematol /Oncol Immunopathol 2014; 13: 45-9.
[3]
Yu JR, Leslie KS. Cryopyrin-associated periodic syndrome: An update on diagnosis and treatment response. Curr Allergy Asthma Rep 2011; 11(1): 12-20.
[http://dx.doi.org/10.1007/s11882-010-0160-9] [PMID: 21104172]
[4]
Fietta P. Autoinflammatory diseases: The hereditary periodic fever syndromes. Acta Biomed 2004; 75(2): 92-9.
[PMID: 15481697]
[5]
Barabanova OV, Konopljova EA, Prodeus AP, Shherbina A. Periodicheskie sindromy. Trudnyj pacient 2007; 2: 43-50. Available from: https://t-pacient.ru/articles/6113/
[6]
Meng G, Zhang F, Fuss I, Kitani A, Strober W. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 2009; 30(6): 860-74.
[http://dx.doi.org/10.1016/j.immuni.2009.04.012] [PMID: 19501001]
[7]
Ozaki E, Campbell M, Doyle SL. Targeting the NLRP3 inflammasome in chronic inflammatory diseases: Current perspectives. J Inflamm Res 2015; 8: 15-27.
[http://dx.doi.org/10.2147/JIR.S51250] [PMID: 25653548]
[8]
Frenkel J, Houten SM, Waterham HR, et al. Clinical and molecular variability in childhood periodic fever with hyperimmunoglobulinaemia D. Rheumatology (Oxford) 2001; 40(5): 579-84.
[http://dx.doi.org/10.1093/rheumatology/40.5.579] [PMID: 11371670]
[9]
Hoffman HM, Wanderer AA, Broide DH. Familial cold autoinflammatory syndrome: Phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 2001; 108(4): 615-20.
[http://dx.doi.org/10.1067/mai.2001.118790] [PMID: 11590390]
[10]
Gattorno M. Cryopyrin-associated periodic syndrome. Questions of Modern Pediatrics 2013; 12(1)
[http://dx.doi.org/10.15690/vsp.v12i1.558]
[11]
Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360(23): 2416-25.
[http://dx.doi.org/10.1056/NEJMoa0810787] [PMID: 19494217]
[12]
Kulanthaivel S, Kaliberdenko VB, Balasundaram K, Shterenshis MV, Scarpellini E, Abenavoli L. Tocilizumab in SARS-CoV-2 patients with the syndrome of cytokine storm: A narrative review. Rev Recent Clin Trials 2021; 16(2): 138-45.
[http://dx.doi.org/10.2174/1574887115666200917110954] [PMID: 32940187]
[13]
Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003; 348(25): 2583-4.
[http://dx.doi.org/10.1056/NEJM200306193482523] [PMID: 12815153]
[14]
Gattorno M, Tassi S, Carta S, et al. Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 2007; 56(9): 3138-48.
[http://dx.doi.org/10.1002/art.22842] [PMID: 17763411]
[15]
Kuemmerle-Deschner JB, Haug I. Canakinumab in patients with cryopyrin-associated periodic syndrome: An update for clinicians. Ther Adv Musculoskelet Dis 2013; 5(6): 315-29.
[http://dx.doi.org/10.1177/1759720X13502629] [PMID: 24294305]
[16]
Brogan PA, Hofer M, Kuemmerle-Deschner JB, et al. Rapid and sustained long-term efficacy and safety of canakinumab in patients with cryopyrin-associated periodic syndrome ages five years and younger. Arthritis Rheumatol 2019; 71(11): 1955-63.
[http://dx.doi.org/10.1002/art.41004] [PMID: 31161734]
[17]
Feist E, Burmester GR. Canakinumab for treatment of cryopyrin-associated periodic syndrome. Expert Opin Biol Ther 2010; 10(11): 1631-6.
[http://dx.doi.org/10.1517/14712598.2010.530653] [PMID: 20955115]
[18]
Toro JR, Aksentijevich I, Hull K, Dean J, Kastner DL. Tumor necrosis factor receptor-associated periodic syndrome: A novel syndrome with cutaneous manifestations. Arch Dermatol 2000; 136(12): 1487-94.
[http://dx.doi.org/10.1001/archderm.136.12.1487] [PMID: 11115159]
[19]
Imagawa T, Nishikomori R, Takada H, et al. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). Clin Exp Rheumatol 2013; 31(2): 302-9.
[PMID: 23380020]
[20]
Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70(6): 896-904.
[http://dx.doi.org/10.1136/ard.2011.151027] [PMID: 21540199]
[21]
Rheumatology: Clinical guidelines / edited by the academician of RAMS E.L. Nasonova. 2010. Available from: https://www. rosmedlib.ru/book/RML0311V3.html
[22]
Salugina SO, Fedorov ES, Kuz'mina NN, Zakharova EY. The interleukin -1 inhibitor canakinumab in the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS): Clinical experience. Sovremennaya Revmatologiya 2014; 8(4): 17-24.
[http://dx.doi.org/10.14412/1996-7012-2014-4-17-24]
[23]
Church LD, Savic S, McDermott MF. Long term management of patients with Cryopyrin-Associated Periodic Syndromes (CAPS): Focus on rilonacept (IL-1 Trap). Biologics 2008; 2(4): 733-42.
[http://dx.doi.org/10.2147/BTT.S3167] [PMID: 19707454]
[24]
Landmann EC, Walker UA. Pharmacological treatment options for cryopyrin-associated periodic syndromes. Expert Rev Clin Pharmacol 2017; 10(8): 855-64.
[http://dx.doi.org/10.1080/17512433.2017.1338946] [PMID: 28586272]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy